International Journal of Clinical Research

Objective To evaluate the efficacy of ticlopidine and aganocine in treating patients with cerebral infarction who have exceeded the thrombolysis time window. Methods A randomized single-double number group control trial was conducted, selecting 52 patients with cerebral infarction who had exceeded the thrombolysis time window between January and December 2024. The 26 patients in the odd-numbered sequence were assigned to the study group and received ticlopidine treatment; the 26 patients in the even-numbered sequence were assigned to the control group and received aganocine treatment, with both groups receiving the same basic treatment. The clinical efficacy and safety indicators of the two groups were compared. Results After treatment, the NIHSS score in the study group decreased more significantly (P<0.05) compared to the control group, and the ADL quality of life score improved more markedly (P<0.05). The recurrence rate of cerebral infarction was 7.7% (2/26) in the study group, which was lower than the 23.1% (6/26) in the control group. There was no statistically significant difference in the incidence of intracranial hemorrhage, systemic bleeding events, and other adverse reactions between the two groups (P>0.05). The inflammatory factor index in the study group after treatment was better than that in the control group (P>0.05). Conclusion In the treatment of patients with cerebral infarction who have exceeded the thrombolysis time window, ticlopidine is superior to aganocine in improving neurological function, enhancing quality of life, and reducing recurrence rates, with comparable safety.

Ticlopidine; Agacurib; Hyperthrombolysis time window; Cerebral infarction